Regen BioPharma Inc (RGBP)

[Krisandtilly]

GAME CHANGER in treating cancer..
"While chemotherapy and radiation therapy non-selectively kill all replicating cells, both cancer and healthy cells, thus causing severe toxicity, targeted therapies such as kinase inhibitors

(e.g.: Gleevec by Novartis $4.7 billion in 2012)1

and proteasome inhibitors
(e.g.: Velcade by J&J and Takeda $2.3 billion in sales in 2012)2

specifically inhibit molecular processes of cancer cells but not other multiplying cells in the body.

Dr. Christine Ichim found that the NR2F6 gene is essential for the process of cancer formation, thus potentially offering a new target for development of targeted therapies," said Dr. Thomas Ichim, Regen BioPharma's Chief Scientific Officer.